Effect of paroxetine treatment on glycaemic control and quality of life in mildly depressed type two diabetic subjects: a double-blind randomised placebo controlled six month trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN55819922

Enrollment

Registered

2006-09-13

Start date

2001-06-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type two diabetes mellitus and depression. Nutritional, Metabolic, Endocrine Type two diabetes mellitus and depression.

Interventions

Paroxetin 20 mg per day or placebo for six months. Blood samples and clinical examination four times during the trial.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Volunteers between 50 and 70 years of age 2. Diagnosed type two diabetes 3. Hba1c more than 7.0% 4. Mild symptoms of depression

Exclusion criteria

Exclusion criteria: 1. Moderate to severe depression based on Diagnostic and Statistical Manual of mental disorders (DSM-IV) criteria 2. Severe diabetic complications 3. Use of warfarin 4. Glaucoma

Design outcomes

Primary

Measure	Time frame
10% decrease in HbA1c.	—

Secondary

Measure	Time frame
20% improvement in quality of life as defined by the RAND-36 health relate quality of life questionnaire.	—

Countries

Finland

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Apr 7, 2026